

University of Nebraska - Lincoln  
DigitalCommons@University of Nebraska - Lincoln

---

Papers in Veterinary and Biomedical Science

Veterinary and Biomedical Sciences, Department of

---

2014

# *Moraxella* Spp. Isolated from Field Outbreaks of Infectious Bovine Keratoconjunctivitis: A Retrospective Study of Case Submissions from 2010 to 2013


John Dustin Loy

*University of Nebraska-Lincoln*, [jdloy@unl.edu](mailto:jdloy@unl.edu)

Bruce W. Brodersen

*University of Nebraska-Lincoln*, [bbrodersen1@unl.edu](mailto:bbrodersen1@unl.edu)

Follow this and additional works at: <http://digitalcommons.unl.edu/vetscipapers>

 Part of the [Biochemistry, Biophysics, and Structural Biology Commons](#), [Cell and Developmental Biology Commons](#), [Immunology and Infectious Disease Commons](#), [Medical Sciences Commons](#), [Veterinary Microbiology and Immunobiology Commons](#), and the [Veterinary Pathology and Pathobiology Commons](#)

---

Loy, John Dustin and Brodersen, Bruce W., "*Moraxella* Spp. Isolated from Field Outbreaks of Infectious Bovine Keratoconjunctivitis: A Retrospective Study of Case Submissions from 2010 to 2013" (2014). *Papers in Veterinary and Biomedical Science*. 277.  
<http://digitalcommons.unl.edu/vetscipapers/277>

This Article is brought to you for free and open access by the Veterinary and Biomedical Sciences, Department of at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Papers in Veterinary and Biomedical Science by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

# *Moraxella* spp. isolated from field outbreaks of infectious bovine keratoconjunctivitis: a retrospective study of case submissions from 2010 to 2013

John Dustin Loy,<sup>1</sup> Bruce W. Brodersen

**Abstract.** Infectious bovine keratoconjunctivitis (IBK), also known as pinkeye, is the most costly eye disease of cattle. The principal etiologic agent of IBK is the Gram-negative bacterium *Moraxella bovis*. However, there have been reports of IBK outbreaks associated with *Moraxella bovoculi*. A retrospective study of IBK diagnostic cases submitted from July 1, 2010 through October 31, 2013 was conducted. Included in the study were 1,042 *Moraxella* isolates from 1,538 swabs of lacrimal secretions collected from 282 herds from 30 U.S. states. *Moraxella* isolates were identified to the species level and were composed of *M. bovoculi* (701 isolates), *M. bovis* (295 isolates), *Moraxella ovis* (5 isolates), and other *Moraxella* spp. (41). Minimum inhibitory concentrations required for 90% growth inhibition (MIC<sub>90</sub>) was calculated for representative isolates. The MIC<sub>90</sub> values for both *M. bovis* and *M. bovoculi* were as follows: ampicillin and ceftiofur: ≤0.25 µg/ml; clindamycin: 2 µg/ml; danofloxacin and enrofloxacin: ≤0.12 µg/ml; florfenicol: 0.5 µg/ml; gentamicin: 1 µg/ml; neomycin: 4 µg/ml; tulathromycin: 2 µg/ml; and tylosin: 8 µg/ml. The MIC<sub>90</sub> values for *M. bovoculi* included the following: chlortetracycline: ≤0.5 µg/ml; oxytetracycline: 4 µg/ml; penicillin: 0.25 µg/ml; spectinomycin: 32 µg/ml; sulfadimethoxine: >256 µg/ml; tiamulin: 1 µg/ml; and trimethoprim–sulfamethoxazole: 4 µg/ml. For *M. bovis*, MIC<sub>90</sub> values included the following: chlortetracycline and oxytetracycline: 1 µg/ml; penicillin: ≤0.12 µg/ml; spectinomycin: 16 µg/ml; sulfadimethoxine: ≤256 µg/ml; tiamulin: ≤0.5 µg/ml; and trimethoprim–sulfamethoxazole: ≤2 µg/ml. The current work describes the frequency of isolation and differences in antimicrobial sensitivity observed among *Moraxella* isolates from case submissions.

**Key words:** Infectious bovine keratoconjunctivitis; *Moraxella bovis*; *Moraxella bovoculi*.

## Introduction

Infectious bovine keratoconjunctivitis (IBK), also known as pinkeye, is a common and costly eye disease of domestic cattle.<sup>28,29</sup> Cattle with IBK demonstrate a variety of clinical signs, including increased tear production, sensitivity to light, and ultimately corneal swelling that progresses into corneal ulceration and possible blindness.<sup>2</sup> Very little is understood about the impacts of IBK on animal welfare<sup>30</sup>; however, pain assessment studies demonstrate that it is a painful and irritating condition.<sup>13</sup> Economic losses in the beef industry can be tremendous, where a 15.9-kg loss in weaning weight per head has been estimated.<sup>20</sup> Midwestern U.S. beef herds report that IBK is endemic in nearly 50% of herds with a prevalence of 8.75 out of 100 cattle affected.<sup>29</sup> Adequate and timely treatment of acute IBK with antimicrobial therapy is frequently challenging due to many animals being remotely pastured or grazed during peak occurrence in the summer months.<sup>26</sup>

The principal etiologic agent for IBK is the Gram-negative bacterium *Moraxella bovis*.<sup>19</sup> One of the major virulence factors of *M. bovis* is a secreted cytotoxin that has been

shown to reproduce IBK lesions in calves.<sup>10</sup> This toxin is a repeats-in toxin (RTX), which forms pores in the membranes of target host cells causing lysis and cell death.<sup>11</sup> *Moraxella bovoculi*, a newly described species in the genus *Moraxella*, has been isolated and characterized in association with IBK in the absence of *M. bovis*.<sup>9</sup> Additional evidence for the role of *M. bovoculi* in the causation of IBK includes secretion of a RTX class cytotoxin similar to that of *M. bovis*.<sup>6</sup> However, studies evaluating vaccine efficacy show a decrease in incidence of IBK neither when *M. bovoculi* was included in an autogenous vaccine formulation<sup>15</sup> nor when subunit *M. bovoculi* cytotoxin was used as a vaccine in calves.<sup>8</sup> Direct inoculation of *M. bovoculi* into scarified calf corneas does not cause IBK lesions, making the direct role of *M. bovoculi* in IBK pathogenesis uncertain.<sup>18</sup> The data indicates that

---

From the School of Veterinary Medicine and Biomedical Sciences, University of Nebraska–Lincoln, Lincoln, NE.

<sup>1</sup>Corresponding Author: John Dustin Loy, School of Veterinary Medicine and Biomedical Sciences, Veterinary Diagnostic Center, Fair Street and East Campus Loop, Lincoln, NE 68583-0907. [jdloy@unl.edu](mailto:jdloy@unl.edu)

although *M. bovoculi* is isolated in cases of IBK, there is no direct evidence supporting a causal role, and temporal associations of *M. bovoculi* and correlation of eye colonization with disease have been difficult to determine.<sup>21</sup> In order to further characterize the microbial populations present in bovine eyes during outbreaks of IBK, a retrospective study was undertaken to assess the composition of *Moraxella* spp. in a large number of diagnostic submissions, as well as to assess the antimicrobial susceptibility patterns to selected antimicrobial agents of representative isolates from diagnostic submissions.

## Materials and methods

Samples included in the current study were comprised of diagnostic laboratory submissions received from July 1, 2010 to October 31, 2013 that had been submitted as diagnostic cases to the Nebraska Veterinary Diagnostic Center (Lincoln, Nebraska). Data was extracted from a laboratory information management software system (LIMS) that includes all diagnostic submissions over the time period. A subset of data was extracted into spreadsheet software including case submissions of swabs of lacrimal secretions collected from bovine eyes during cases of IBK in beef or dairy herds. For some diagnostic submissions, a specific state or geographic region where the herd was located in which the sample was taken was not included on the submission information. Herd data was based on unique accession numbers assigned to each case. Individual data was determined based on a unique individual identification number present on a case submission form. Isolation of *Moraxella* spp. on eye swabs was conducted by trained technicians following standard operating procedures in an American Association of Veterinary Laboratory Diagnosticians (AAVLD) fully accredited laboratory. Data entry into LIMS was performed by the technician, and results were reviewed by a laboratory manager and a case coordinator for accuracy. The protocol used by all trained technicians in the laboratory at the time period, to determine if viable *Moraxella* spp. were present in the samples, was as follows: Swabs were streaked onto tryptic soy agar containing 5% sheep's blood and incubated for 18–24 hr at 37°C with 5% CO<sub>2</sub> supplementation. Bacterial colonies with morphology consistent with members of the genus *Moraxella* were further screened for oxidase production. Colonies positive for oxidase production were then subjected to Gram staining and were subcultured for purity. All subcultured organisms that were characterized as Gram-negative rods or coccobacilli by Gram stain were subjected to molecular speciation. Isolates were subsequently identified as *M. bovis*, *M. bovoculi*, or *Moraxella ovis* based on a polymerase chain reaction (PCR) assay and a subsequent restriction fragment length polymorphism analysis that targets the 16S-23S intergenic spacer region in combination with phenotypic tests as needed.<sup>4</sup> Some isolates could not be definitively identified based on PCR data and phenotypic data, and were categorized as *Moraxella* sp.

For PCR testing, genomic DNA was extracted from 24-hr subculture growth by picking out several well-isolated colonies with a sterile stick and then resuspending the colonies into 100 µl of nuclease-free water to a 1–2 McFarland standard turbidity. Cell suspensions were boiled at 100°C for 10 min to lyse bacterial cells. Cell debris was clarified by centrifugation at 15,700 × *g* for 2 min. Extracted nucleic acid was subjected to PCR using primers<sup>a</sup> ISRdown (5'-GTGAAGTCGTAACAAGGTAGCCGT-3') and ISRup (5'-ACCGACGCTTATCGCAGGCTATCA-3').<sup>4</sup> The PCR master mix<sup>b</sup> consisted of 50 µl, which contained nuclease-free H<sub>2</sub>O (32.1 µl), 5.0 µl of 10× reaction buffer, 4.0 µl of MgCl<sub>2</sub> (50 mM), 0.5 µl of deoxyribonucleotide triphosphates (100 mM), 2.5 µl of ISRup (10 µM), 2.5 µl of ISRdown (10 µM), 0.4 µl of *Taq* polymerase (5 U/µl), and 3.0 µl of template DNA. The PCR reactions were subjected to thermocycling under the following conditions; 95°C for 60 sec, then 40 cycles of 95°C for 30 sec, 55°C for 30 sec, and 72°C for 30 sec and a final extension of 72°C for 7 min. Amplicons were then digested with restriction endonuclease *AfaI*<sup>c</sup> and subjected to a 60-min digestion at 37°C. Digested DNA (15 µl) was resolved using capillary gel electrophoresis.<sup>d</sup> Interpretation of molecular weight fragments corresponding to *M. bovoculi*, *M. ovis*, and *M. bovis* was 450- and 150-bp, 600-bp, and 650-bp fragments, respectively.

As part of the diagnostic workup of each case submission, representative isolates were selected on a herd level based on similar colony growth characteristics and PCR speciation. The representative isolates were then subjected to antimicrobial sensitivity testing. Because of the small number of *M. ovis* isolates and possible diversity within the *Moraxella* sp. isolated, these organisms were excluded from the antimicrobial susceptibility analysis. To conduct in vitro antimicrobial sensitivity, a broth microdilution system was used following Clinical Laboratory Standards Institute (CLSI) guidelines.<sup>12</sup> Several colonies of pure culture were suspended into 10 ml of sterile demineralized water to a 0.5 McFarland standard and vortexed to ensure uniform resuspension. Inoculation density was confirmed using a calibrated nephelometer. A 10-µl aliquot of the resuspended organism was then inoculated into 11 ml of sterile inoculation media and vortexed to ensure uniform resuspension. A 100-µl aliquot of culture per well was then inoculated into bovine and/or porcine antimicrobial susceptibility panels<sup>e</sup> with an autoinoculator. Samples were incubated at 35°C for 18 hr without carbon dioxide supplementation and were read automatically with the minimal inhibitory concentration (MIC) determined using an automated system.<sup>f</sup> The auto-read values were confirmed manually by observation as necessary. Quality control organisms used for assays include *Staphylococcus aureus* (ATCC 29213), *Enterococcus faecalis* (ATCC 29212), and *Escherichia coli* (ATCC 25922). No specific CLSI-approved interpretative criteria exist for *Moraxella* spp. in cattle, therefore interpretive criteria established for bovine respiratory disease or other Gram-negative veterinary isolates as available were used, with organisms classified as susceptible (S),

**Table 1.** Selected antimicrobial drugs utilized in broth microdilution testing for minimum inhibitory concentrations, the range of concentrations evaluated for each antimicrobial, and interpretive criteria (susceptible, intermediate, or resistant) applied to each antimicrobial tested.

Antimicrobial	Concentration(s) tested (µg/ml)	Susceptible	Intermediate	Resistant
Ampicillin	0.25–16	≤0.5	1	≥2
Ceftiofur	0.25–8	≤2	4	≥8
Chlortetracycline	0.5–8	≤2	4	≥8
Clindamycin	0.25–16	≤0.5	1–2	≥4
Danofloxacin	0.12–1	≤0.25	*	*
Enrofloxacin	0.12–2	≤0.25	0.5–1	≥2
Florfenicol	0.25–8	≤2	4	≥8
Gentamicin	1–16	≤2	4	≥8
Neomycin	4–32	*	*	*
Oxytetracycline	0.5–8	≤2	4	≥8
Penicillin	0.12–8	≤0.25	0.5	≥1
Spectinomycin	8–64	≤32	64	≥128
Sulfadimethoxine	256	≤256		>256
Tiamulin	0.5–32	≤16		≥32
Tilmicosin	4–64	≤8	16	≥32
Trimethoprim–sulfamethoxazole	2/38†	<2/38		≥2/38
Tulathromycin	1–64	≤16	32	≥64
Tylosin	0.5–32	*	*	*

\* No interpretive criteria available.

† A single concentration of 2 µg/ml trimethoprim in combination with 38 µg/ml sulfamethoxazole (2/38) was tested.

intermediate (I), or resistant (R; Table 1).<sup>12</sup> Breakpoints were not available for neomycin and tylosin. For trimethoprim–sulfamethoxazole and sulfadimethoxine only a single drug concentration was tested. Percent susceptibility (% susceptible) was determined by dividing the number of organisms with MIC values that fell into a susceptible MIC breakpoint (numerator) by the total tested (denominator) and multiplying by 100. The MIC<sub>50</sub> and MIC<sub>90</sub> values were defined as the concentration of antibiotic that was capable of inhibiting growth of 50% and 90% of total tested isolates.


## Results

A total of 1,538 samples were included in the data set. Of these, 600 had no growth of *Moraxella* spp. or were too contaminated with overgrowth to determine if there were *Moraxella* organisms present in the specimen. Out of this total, 938 swabs had growth of 1 or more *Moraxella* spp., and the total number of isolates subjected to identification was 1,042 as some had multiple species present. Submitted samples included case submissions from cases of IBK in 30 states. Submissions from 29 out of 30 states had at least 1 *Moraxella* sp. isolated. The number of submitted samples on a state-by-state basis that contained at least 1 *Moraxella* spp. isolated as well as the number of herds from which these samples originated, is indicated (Fig. 1). For 261 herds, geographic information was sufficient to determine the state of origin for the submission. On individual animal level 938

submissions were identified. The frequency of isolation of *Moraxella* in individuals included: *M. bovis*: 193; *M. bovoculi*: 600; *M. ovis*: 4; *Moraxella* sp.: 37; *M. bovis* and *M. bovoculi*: 99; *M. bovoculi* and *Moraxella* sp.: 1; *M. bovoculi* and *M. ovis*: 1; *M. bovis* and *Moraxella* sp.: 3 (Table 2).

On a herd level, 282 total herds were identified. The frequency of isolation of *Moraxella* spp. in herds included: *M. bovis*: 18; *M. bovoculi*: 140; *M. ovis*: 2; *Moraxella* sp.: 7; *M. bovis* and *M. bovoculi*: 102; *M. bovoculi* and *Moraxella* sp.: 2; *M. bovoculi* and *M. ovis*: 1; *M. bovoculi* and *M. ovis*: 1; *M. bovis* and *Moraxella* sp.: 1; *M. bovis*, *M. bovoculi*, and *M. ovis*: 1 (Table 2).

For *M. bovoculi*, 213 total isolates were subjected to MIC testing against 18 antimicrobials with a range of concentrations (Table 1). MIC<sub>90</sub> values were as follows: ampicillin, ≤0.25 µg/ml; ceftiofur, ≤0.25 µg/ml; chlortetracycline, ≤0.5 µg/ml; clindamycin, 2 µg/ml; danofloxacin and enrofloxacin, ≤0.12 µg/ml; florfenicol, 0.5 µg/ml; gentamicin, 1 µg/ml; neomycin and oxytetracycline, 4 µg/ml; penicillin, 0.25 µg/ml; spectinomycin, 32 µg/ml; sulfadimethoxine, >256 µg/ml; tiamulin, 1 µg/ml; trimethoprim–sulfamethoxazole, 4 µg/ml; tulathromycin, 2 µg/ml; and tylosin, 8 µg/ml (Table 3). The total susceptible phenotypes observed for *M. bovoculi* were as follows: ampicillin, 99%; ceftiofur, 100%; chlortetracycline, 93%; clindamycin, 11%; danofloxacin, 98%; enrofloxacin, 98%; florfenicol, 92%; gentamicin, 98%; neomycin, not determined (ND); oxytetracycline, 85%; penicillin, 96%; spectinomycin, 86%; sulfadimethoxine, 86%;



**Figure 1.** Number and state-by-state distribution of case submissions that at least 1 *Moraxella* spp. was isolated from bovine ocular swabs. States with at least 1 *Moraxella* isolate included in the analysis are shaded in dark gray. Numbers on the state indicates the total positive case submissions received in the period, and the number in parentheses indicates the number of positive herds included in each state over the period from July 1, 2010 to October 31, 2013.

**Table 2.** Profile of *Moraxella* spp. isolated from lacrimal secretion swab cultures ( $n = 1,042$ ).\*

Species isolated	No. of herds yielding the indicated species	No. of individuals yielding the indicated species
	(1)	(2)
<i>Moraxella bovis</i>	18	193
<i>Moraxella bovoculi</i>	140	600
<i>Moraxella ovis</i>	2	4
<i>Moraxella</i> sp.	7	37
<i>M. bovis</i> and <i>M. bovoculi</i>	102	99
<i>M. bovoculi</i> and <i>Moraxella</i> sp.	2	1
<i>M. bovoculi</i> and <i>M. ovis</i>	1	1
<i>M. bovis</i> and <i>Moraxella</i> sp.	2	3
<i>M. bovis</i> , <i>M. ovis</i> , and <i>M. bovoculi</i>	1	0

\* The number of herds with the corresponding species composition of isolated organisms is indicated in column (1). Column (2) indicates the number of herds with the corresponding species composition isolated from samples.

tiamulin, 99%; tilmicosin, 92%; trimethoprim–sulfamethoxazole, 87%; tulathromycin, 92%; and tylosin, ND (Table 3).

For *M. bovis*, 106 total isolates were subjected to MIC testing against 18 antimicrobials with a range of concentra-

tions (Table 1). The MIC<sub>90</sub> values were as follows: ampicillin,  $\leq 0.25$   $\mu\text{g/ml}$ ; ceftiofur,  $\leq 0.25$   $\mu\text{g/ml}$ ; chlortetracycline, 1  $\mu\text{g/ml}$ ; clindamycin, 2  $\mu\text{g/ml}$ ; danofloxacin and enrofloxacin,  $\leq 0.12$   $\mu\text{g/ml}$ ; florfenicol, 0.5  $\mu\text{g/ml}$ ; gentamicin, 1  $\mu\text{g/ml}$ ; neomycin, 4  $\mu\text{g/ml}$ ; oxytetracycline, 1  $\mu\text{g/ml}$ ; penicillin,  $\leq 0.12$   $\mu\text{g/ml}$ ; spectinomycin, 16  $\mu\text{g/ml}$ ; sulfadimethoxine,  $\leq 256$   $\mu\text{g/ml}$ ; tiamulin,  $\leq 0.5$   $\mu\text{g/ml}$ ; trimethoprim–sulfamethoxazole,  $\leq 2$   $\mu\text{g/ml}$ ; tulathromycin, 2  $\mu\text{g/ml}$ ; and tylosin, 8  $\mu\text{g/ml}$  (Table 4). The total susceptible phenotypes observed for *M. bovis* were as follows: ampicillin, 99%; ceftiofur, 100%; chlortetracycline, 91%; clindamycin, 21%; danofloxacin, 100%; enrofloxacin, 100%; florfenicol, 100%; gentamicin, 100%; neomycin, ND; oxytetracycline, 96%; penicillin, 99%; spectinomycin, 100%; sulfadimethoxine, 98%; tiamulin, 99%; tilmicosin, 100%; trimethoprim–sulfamethoxazole, 98%; tulathromycin, 94%; and tylosin, ND (Table 4).

## Discussion

While previous data indicated that *M. bovoculi* is isolated in association with outbreaks of IBK in the absence of *M. bovis*,<sup>9,21</sup> the current study has characterized the composition of *Moraxella* isolates associated with IBK from a large number of geographically diverse case submissions in the United States. Other authors have characterized genetic diversity using fingerprinting among *Moraxella* spp. in other countries but have not examined these on a herd or individual animal level.<sup>27</sup> It was observed in the current study that *M. bovoculi*

**Table 3.** Count of *Moraxella bovoculi* isolates with the minimum inhibitory concentration (MIC) for each antibiotic tested. Additionally, the MIC required to inhibit 50% and 90% (MIC<sub>50</sub> and MIC<sub>90</sub>, respectively) of each isolate as well as the total percentage of *M. bovoculi* isolates that were susceptible to each antibiotic are included (*n* = 213 isolates).

Antimicrobial	MIC (µg/ml)												MIC <sub>50</sub>	MIC <sub>90</sub>	% susceptible	
	0.12	0.25	0.5	1	2	4	8	16	32	64	≤256	>256				
Ampicillin		211		2										≤0.25	≤0.25	99
Ceftiofur		207	4											≤0.25	≤0.25	100
Chlortetracycline			185	11	2	11		4*						≤0.5	≤0.5	93
Clindamycin		11	13	119	62	4	2	2*						1	2	11
Danofloxacin	207	2		4*										≤0.12	≤0.12	98
Enrofloxacin	207	2			4*									≤0.12	≤0.12	98
Florfenicol		28	164	2	2	11	4*							0.5	0.5	92
Gentamicin				204	4	2	2							1	1	98
Neomycin						200	9	2	2					4	4	†
Oxytetracycline			153	26	2	11	19*							≤0.5	4	85
Penicillin	183	21	4	2	2									≤0.12	0.25	96
Spectinomycin							45	142	9	17*				16	32	92
Sulfadimethoxine											183	30		≤256	>256	86
Tiamulin			181	26		2	2		2					≤0.5	1	99
Tilmicosin						179	17	2	11	4				≤4	8	92
Trimethoprim– sulfamethoxazole‡					185	28§								≤2	4	87
Tulathromycin				179	13		4			6	6			≤1	2	92.0
Tylosin				2	2	147	70							4	8	†

\* Endpoint of > for the MIC indicated.

† No interpretive criteria available.

‡ A single concentration of 2 µg/ml trimethoprim in combination with 38 µg/ml sulfamethoxazole (2/38) was tested.

§ Indicates MIC of >2 µg/ml as additional concentrations were not evaluated.

was the only *Moraxella* sp. isolated from the majority of case submissions, when evaluated at either the herd or individual level. These findings were unexpected, given that *M. bovis* has been isolated from experimentally infected calves up to 54 days following inoculation, and thus it was thought that *M. bovis* would be the predominant organism isolated in association with IBK outbreaks.<sup>17</sup> However, recovery of *M. bovis* may be variable as pathogenesis studies have shown that *M. bovis* was not observed on the conjunctival surface, using light microscopy, 10-hr postinoculation when introduced in gnotobiotic calves.<sup>23</sup> Other studies have shown that *M. bovoculi* can be isolated from ulcers in calves experimentally inoculated with *M. bovis*.<sup>18</sup> Epidemiologic investigations have also failed to establish a temporal relationship between prior exposure and clinical IBK outbreaks with isolations of *M. bovoculi*.<sup>21</sup> Analysis of the speciation data in the current study indicates that *M. bovoculi* is present and viable in most of the submissions in higher numbers than *M. bovis*. *Moraxella bovis*, when cultured, was frequently isolated in association with *M. bovoculi*, and was the sole *Moraxella* spp. isolated in only 18 of the 282 herd submissions. The generally accepted method for sample collection for IBK culture is to place the swab in the ventral conjunctival sac to sample lacrimal secretions. Differences and variability in and among sampling methods and timing of

collection may result in samples that may not be representative of all organisms present in the eye conjunctiva. Additionally, the isolation of *M. ovis* from only 5 swabs indicates that this species, at least in this set of samples, is likely not significantly contributing to IBK in cattle.

Previous studies have evaluated antimicrobial resistance patterns in *M. bovis* and *M. bovoculi* in smaller collections of isolates individually.<sup>5,25</sup> Additionally, a study assessing the diversity of *Moraxella* spp. in IBK cases from Uruguay evaluated antimicrobial susceptibility; however, the methods utilized disk diffusion and did not measure zone sizes for interpretation, as recommended by the CLSI, and did not use minimum inhibitory concentration testing making comparison with this data difficult.<sup>27</sup> The antimicrobial susceptibility data from the present study, for *M. bovoculi*, is similar to a study that examined 57 isolates from California.<sup>5</sup> However, there were some differences observed. *Moraxella bovoculi* isolates showed a reduced level of in vitro susceptibility to the tetracycline class drugs, where the MIC<sub>90</sub> for oxytetracycline was found to be 4 µg/ml instead of 1 µg/ml. This is a four-fold increase in MIC<sub>90</sub> value over the previously published data.<sup>6</sup> Contrastingly, the MIC<sub>90</sub> for *M. bovis* against oxytetracycline was previously reported as 32 µg/ml,<sup>25</sup> whereas a much lower MIC<sub>90</sub> of 1 µg/ml was found in the current study. The MIC<sub>90</sub> of tulathromycin for both *M. bovis*

**Table 4.** Count of *Moraxella bovis* isolates with the minimum inhibitory concentration (MIC) for each antibiotic tested. Additionally, the MIC required to inhibit 50% and 90% (MIC<sub>50</sub> and MIC<sub>90</sub>, respectively) of each isolate as well as the total percentage of *M. bovis* isolates that were susceptible to each antibiotic are included (*n* = 106 isolates).

Antimicrobial	MIC (µg/ml)												MIC <sub>50</sub>	MIC <sub>90</sub>	% susceptible	
	0.12	0.25	0.5	1	2	4	8	16	32	64	≤256	>256				
Ampicillin		105			1									≤0.25	≤0.25	99
Ceftiofur		104	2											≤0.25	≤0.25	100
Chlortetracycline			93	2	1		10*							≤0.5	1	91
Clindamycin			22	67	15	2								1	2	21
Danofloxacin	100	6												≤0.12	≤0.12	100
Enrofloxacin	103	3												≤0.12	≤0.12	100
Florfenicol		72	33	1										0.5	0.5	100
Gentamicin				106										1	1	100
Neomycin						105	1							4	4	†
Oxytetracycline			94	8		1	3							≤0.5	1	96
Penicillin	99	6	1											≤0.12	≤0.12	99
Spectinomycin							98	8						16	16	100
Sulfadimethoxine										104	2			≤256	≤256	98
Tiamulin			98	6	1	1								≤0.5	≤0.5	99
Tilmicosin						95	11							≤4	8	100
Trimethoprim–sulfamethoxazole‡					104	2§								≤2	≤2	98
Tulathromycin				104	1			1		6				≤1	2	94
Tylosin				8	21	45	29	3						4	8	†

\* Endpoint of > for the MIC indicated.

† No interpretive criteria available.

‡ A single concentration of 2 µg/ml trimethoprim in combination with 38 µg/ml sulfamethoxazole (2/38) was tested.

§ Indicates MIC of >2 µg/ml as additional concentrations were not evaluated.

and *M. bovoculi* fell within the susceptible range of 2 µg/ml. However, there were 16 isolates of *M. bovoculi* with MIC values of 8 or greater for tulathromycin, with 6 of these isolates with MIC values of 64 µg/ml or greater. This is important to note, as oxytetracycline and tulathromycin are 2 antimicrobials with label claims for treatment of IBK associated with *M. bovis*.

Other antimicrobial drugs have been reported to be effective at treating IBK, including penicillin,<sup>1,3</sup> cloxacillin benzathine,<sup>17</sup> ceftiofur,<sup>14</sup> clindamycin,<sup>24</sup> florfenicol,<sup>7</sup> and tilmicosin.<sup>31</sup> A systematic review of randomized clinical trials examining IBK pharmacological studies indicated that direct comparisons between therapies were lacking, making drug comparisons challenging.<sup>22</sup> Evaluation of antimicrobial efficacy for therapy cannot be determined based on susceptibility patterns; however, in vitro testing of *M. bovis* and *M. bovoculi* indicate susceptibility to most of the antimicrobials, with MIC<sub>90</sub> values falling into the susceptible category. The lowest percentage of susceptibility was seen with clindamycin; however, a significant number of organisms fell in the intermediate interpretive category for clindamycin (70 and 17 for *M. bovoculi* and *M. bovis*, respectively) making the number of isolates in the resistant category quite low, with a MIC<sub>90</sub> of 2 µg/ml for both *Moraxella* species. While previous reports of antimicrobial susceptibility testing have shown elevated

resistance to penicillin for *M. bovoculi* (12.3%),<sup>5</sup> data in the present study showed only a 4% level of resistance. The antimicrobial resistance patterns appear similar between geographically distinct *M. bovis* and *M. bovoculi* isolates, indicating that infections with either or both organisms show similar susceptibility patterns as previously noted.<sup>5</sup> However, it should be noted that there are some small differences, as the MIC<sub>90</sub> of *M. bovoculi* for oxytetracycline was higher than for *M. bovis* (4 µg/ml compared with 1 µg/ml).

Differences in these susceptibility patterns may be indicative of regional preference for antimicrobial usage to treat IBK, and the emergence of these patterns may be based on selective pressure. Other factors that may influence this difference include transmission of resistance genotypes on a regional level, as all of the previously tested *M. bovoculi* isolates were from California and the current study was biased toward Midwestern U.S. states but included other states. Antimicrobial treatment prior to sampling was unable to be determined as this was not routinely included in the case histories on the submissions forms. However, prior treatment with antimicrobials may affect in vitro susceptibility data, and knowledge of a treatment history may enable more analysis of these patterns.

In conclusion, *M. bovoculi* is the most prevalent and frequent of the *Moraxella* sp. isolated in IBK cases in cattle

submitted to the Nebraska Veterinary Diagnostic Center on both individual and herd levels. Over 600 of the 1,042 isolates tested were *M. bovoculi*. In nearly half (102/282) of the herds tested, both *M. bovoculi* and *M. bovis* were isolated from 1 or more animals in those herds. The frequency of co-isolations may indicate that *M. bovoculi* may be serving as an opportunistic agent or colonizing eyes in conjunction with *M. bovis*, which has been shown experimentally to induce characteristic ulcers in gnotobiotic calves.<sup>23</sup> Further work should be conducted to elucidate the temporal factors and role of coinfections with *M. bovoculi* and *M. bovis* in IBK pathogenesis that would enable further interpretation of this data.

### Acknowledgements

The authors would like to thank Dr. John Mayer and Dr. Eric Moore from Merck Animal Health for facilitating diagnostic submissions from IBK outbreaks. The authors would like to thank Roxane Ellis, for assistance with records retrieval and LIMS searches; the director of the NVDC, Dr. Alan Doster, for support of this project; and the staff of the UNL VDC Bacteriology lab: Debra Royal, Jamie Bauman, Laura Pike, and Marijana Bradaric.

### Sources and manufacturers

- a. Integrated DNA Technologies Inc., Coralville, IA.
- b. *Taq* DNA polymerase, PCR master mix, and 100 mM dNTP set; Life Technologies, Grand Island, NY.
- c. *AfaI* (*RsaI*), Invitrogen, Life Technologies, Grand Island, NY.
- d. QIAxcel advanced instrument, Qiagen Inc., Valencia, CA.
- e. Bovine/porcine with tulathromycin MIC plate, Trek Diagnostic Systems, Thermo Fisher Scientific Inc., Waltham, MA.
- f. Sensititre Microbiology System Trek Diagnostic Systems, Thermo Fisher Scientific Inc., Waltham, MA.

### Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

### Funding

The author(s) received no financial support for the research of this article. Financial support for the authorship and publication of this article was provided by the University of Nebraska–Lincoln, Institute of Agriculture and Natural Resources, School of Veterinary Medicine and Biomedical Sciences, Veterinary Diagnostic Center.

### References

1. Abeynayake P, Cooper BS: 1985, Procaine penicillin by subconjunctival injection in the treatment of infectious bovine keratoconjunctivitis. *N Z Vet J* 33:6–7.
2. Alexander D: 2010, Infectious bovine keratoconjunctivitis: a review of cases in clinical practice. *Vet Clin North Am Food Anim Pract* 26:487–503.
3. Allen LJ, George LW, Willits NH: 1995, Effect of penicillin or penicillin and dexamethasone in cattle with infectious bovine keratoconjunctivitis. *J Am Vet Med Assoc* 206:1200–1203.
4. Angelos JA, Ball LM: 2007, Differentiation of *Moraxella bovoculi* sp. nov. from other coccoid moraxellae by the use of polymerase chain reaction and restriction endonuclease analysis of amplified DNA. *J Vet Diagn Invest* 19:532–534.
5. Angelos JA, Ball LM, Byrne BA: 2011, Minimum inhibitory concentrations of selected antimicrobial agents for *Moraxella bovoculi* associated with infectious bovine keratoconjunctivitis. *J Vet Diagn Invest* 23:552–555.
6. Angelos JA, Ball LM, Hess JF: 2007, Identification and characterization of complete RTX operons in *Moraxella bovoculi* and *Moraxella ovis*. *Vet Microbiol* 125:73–79.
7. Angelos JA, Dueger EL, George LW, et al.: 2000, Efficacy of florfenicol for treatment of naturally occurring infectious bovine keratoconjunctivitis. *J Am Vet Med Assoc* 216:62–64.
8. Angelos JA, Lane VM, Ball LM, Hess JF: 2010, Recombinant *Moraxella bovoculi* cytotoxin-ISCAM matrix adjuvanted vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis. *Vet Res Commun* 34:229–239.
9. Angelos JA, Spinks PQ, Ball LM, George LW: 2007, *Moraxella bovoculi* sp. nov., isolated from calves with infectious bovine keratoconjunctivitis. *Int J Syst Evol Microbiol* 57:789–795.
10. Beard MK, Moore LJ: 1994, Reproduction of bovine keratoconjunctivitis with a purified haemolytic and cytotoxic fraction of *Moraxella bovis*. *Vet Microbiol* 42:15–33.
11. Clinkenbeard KD, Thiessen AE: 1991, Mechanism of action of *Moraxella bovis* hemolysin. *Infect Immun* 59:1148–1152.
12. Clinical Laboratory Standards Institute (CLSI): 2013, Performance standards for antimicrobial disk and dilution susceptibility test for bacteria isolated from animals; approved standard—fourth edition. CLSI document VET01-A4 and VET01-S2. Wayne, PA.
13. Dewell RD, Millman ST, Gould SA, et al.: 2014, Evaluating approaches to measuring ocular pain in bovine calves with corneal scarification and infectious bovine keratoconjunctivitis-associated corneal ulcerations. *J Anim Sci* 92:1161–1172.
14. Dueger EL, George LW, Angelos JA, et al.: 2004, Efficacy of a long-acting formulation of ceftiofur crystalline-free acid for the treatment of naturally occurring infectious bovine keratoconjunctivitis. *Am J Vet Res* 65:1185–1188.
15. Funk L, O'Connor AM, Maroney M, et al.: 2009, A randomized and blinded field trial to assess the efficacy of an autogenous vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis (IBK) in beef calves. *Vaccine* 27:4585–4590.
16. George LW, Keefe T, Daigneault J: 1989, Effectiveness of two benzathine cloxacillin formulations for treatment of naturally occurring infectious bovine keratoconjunctivitis. *Am J Vet Res* 50:1170–1174.
17. George LW, Smith JA: 1985, Treatment of *Moraxella bovis* infections in calves using a long-acting oxytetracycline formulation. *J Vet Pharmacol Ther* 8:55–61.
18. Gould S, Dewell R, Tofflemire K, et al.: 2013, Randomized blinded challenge study to assess association between *Moraxella bovoculi* and infectious bovine keratoconjunctivitis in dairy calves. *Vet Microbiol* 164:108–115.
19. Henson JB, Grumbles LC: 1960, Infectious bovine keratoconjunctivitis. I. Etiology. *Am J Vet Res* 21:761–766.
20. Killinger AH, Valentine D, Mansfield ME, et al.: 1977, Economic impact of infectious bovine keratoconjunctivitis in beef calves. *Vet Med Small Anim Clin* 72:618–620.



21. O'Connor AM, Shen HG, Wang C, Opriessnig T: 2012, Descriptive epidemiology of *Moraxella bovis*, *Moraxella bovoculi* and *Moraxella ovis* in beef calves with naturally occurring infectious bovine keratoconjunctivitis (pinkeye). *Vet Microbiol* 155:374–380.
22. O'Connor AM, Wellman NG, Evans RB, Roth DR: 2006, A review of randomized clinical trials reporting antibiotic treatment of infectious bovine keratoconjunctivitis in cattle. *Anim Health Res Rev* 7:119–127.
23. Rogers DG, Cheville NF, Pugh GW Jr: 1987, Pathogenesis of corneal lesions caused by *Moraxella bovis* in gnotobiotic calves. *Vet Pathol* 24:287–295.
24. Senturk S, Cetin C, Temizel M, Ozel E: 2007, Evaluation of the clinical efficacy of subconjunctival injection of clindamycin in the treatment of naturally occurring infectious bovine keratoconjunctivitis. *Vet Ophthalmol* 10:186–189.
25. Shryock TR, White DW, Werner CS: 1998, Antimicrobial susceptibility of *Moraxella bovis*. *Vet Microbiol* 61:305–309.
26. Snowden GD, Van Vleck LD, Cundiff LV, Bennett GL: 2005, Genetic and environmental factors associated with incidence of infectious bovine keratoconjunctivitis in preweaned beef calves. *J Anim Sci* 83:507–518.
27. Sosa V, Zunino P: 2013, Diversity of *Moraxella* spp. strains recovered from infectious bovine keratoconjunctivitis cases in Uruguay. *J Infect Dev Ctries* 7:819–824.
28. Ward JK, Nielson MK: 1979, Pinkeye (bovine infectious keratoconjunctivitis) in beef cattle. *J Anim Sci* 49:361–366.
29. Webber JJ, Selby LA: 1981, Risk factors related to the prevalence of infectious bovine keratoconjunctivitis. *J Am Vet Med Assoc* 179:823–826.
30. Williams DL: 2010, Welfare issues in farm animal ophthalmology. *Vet Clin North Am Food Anim Pract* 26:427–435.
31. Zielinski GC, Piscitelli HG, Perez-Monti H, et al.: 2002, Efficacy of different dosage levels and administration routes of tilmicosin in a natural outbreak of infectious bovine keratoconjunctivitis (pinkeye). *Vet Ther* 3:196–205.